Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?

Drug Development Research

Volumn 75, Issue , 2014, Pages S7-S10

  Murdaca, Giuseppe ^a   Gulli, Rossella ^b   Spanò, Francesca ^a   Mandich, Paola ^b   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

etanercept; lymphotoxin ; TNF gene polymorphisms

Indexed keywords

EPITOPE; ETANERCEPT; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; LYMPHOTOXIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; GENE INTERACTION; GENE LOCUS; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; PREDICTION; PROGNOSIS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; GENETICS; GENOTYPE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; LYMPHOTOXIN-ALPHA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910033378     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21185     Document Type: Review

References (28)

1. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Peña AS,. 1996. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43: 456-463.
2. Chang J, Girgis L,. 2007. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician 36: 1035-1038.
3. Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL,. 2008a. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 69: 510-512.
4. Ciprandi G, Colombo BM, Murdaca G, De Amici M,. 2008b. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 63: 945-946.
5. Colombo BM, Murdaca G, Caiti M, Rodriguez G, Grassia L, Rossi E, Indiveri F, Puppo F,. 2007. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 1108: 121-126.
6. Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, Nobili F, Pisciotta L, Bertolini S, Moccetti T, et al. 2009. Traditional and nontraditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 8: 309-315.
7. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, et al. 2004. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50: 2750-2756.
8. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, et al. 2007. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 57: 1426-1430.
9. Jančic I, Arsenovic-Ranin N, Sefik-Bukilica M, Zivojinovic S, Damjanov N, Spasovski V, Srzentic S, Stankovic B, Pavlovic S,. 2013. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 33: 1481-1486.
10. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC,. 2005. The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 44: 547-552.
11. Murdaca G, Colombo BM, Puppo F,. 2009. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 22: 557-565.
12. Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F,. 2010. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 11: 437-439.
13. Murdaca G, Colombo BM, Puppo F,. 2011a. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 11: 56-60.
14. Murdaca G, Colombo BM, Puppo F,. 2011b. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 47: 277-288.
15. Murdaca G, Colombo BM, Puppo F,. 2011c. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 6: 487-495.
16. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F,. 2012a. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 11: 1-5.
17. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F,. 2012b. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224: 309-317.
18. Murdaca G, Colombo BM, Contini P, Puppo F,. 2012c. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 32: 277-279.
19. Murdaca G, Spanò F, Puppo F,. 2013a. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf 12: 187-193.
20. Murdaca G, Spanò F, Cagnati P, Puppo F,. 2013b. Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. Redox Rep 18: 95-99.
21. Murdaca G, Spanò F, Miglino M, Puppo F,. 2013c. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy 5: 113-115.
22. Murdaca G, Spanò F, Puppo F,. 2013d. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 12: 801-804.
23. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, et al. 2003. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62: 526-529.
24. Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, et al. 2010. Association between anti tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 69: 1315-1320.
25. Puppo F, Murdaca G, Ghio M, Indiveri F,. 2005. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 4: 537-541.
26. Schmeling H, Horneff G,. 2007. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 27: 383-386.
27. Schotte H, Schlüter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M,. 2005. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 64: 575-581.
28. Taylor PC,. 2003. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3: 323-328.